OBJECTIVES: To test the hypothesis that a screening and treatment intervention for early cryptococcal infection would improve survival among HIV-infected individuals with low CD4 cell counts. METHODS: Newly enrolled patients at Family AIDS Care and Education Services (FACES) in Kenya with CD4 ≤ 100 cells/μl were tested for serum cryptococcal antigen (sCrAg). Individuals with sCrAg titre ≥ 1:2 were treated with high-dose fluconazole. Cox proportional hazard models of Kaplan-Meier curves were used to compare survival among individuals with CD4 ≤ 100 cells/μl in the intervention and historical control groups. RESULTS: The median age was 34 years [IQR: 29,41], 54% were female, and median CD4 was 43 cells/μl [IQR: 18,71]. Follow-up time was 1224 person-years. In the intervention group, 66% (514/782) were tested for sCrAg; of whom, 11% (59/514) were sCrAg positive. Mortality was 25% (196/782) in the intervention group and 25% (191/771) in the control group. There was no significant difference between the intervention and control group in overall survival [hazard ratio (HR): 1.1 (95%CI:0.9,1.3)] or three-month survival [HR: 1.0 (95%CI:0.8,1.3)]. Within the intervention group, sCrAg-positive individuals had significantly lower survival rates than sCrAg-negative individuals [HR:1.8 (95%CI: 1.0, 3.0)]. CONCLUSIONS: A screening and treatment intervention to identify sCrAg-positive individuals and treat them with high-dose fluconazole did not significantly improve overall survival among HIV-infected individuals with CD4 counts ≤ 100 cells/μl compared to a historical control, perhaps due to intervention uptake rates or poor efficacy of high-dose oral fluconazole.
OBJECTIVES: To test the hypothesis that a screening and treatment intervention for early cryptococcal infection would improve survival among HIV-infected individuals with low CD4 cell counts. METHODS: Newly enrolled patients at Family AIDS Care and Education Services (FACES) in Kenya with CD4 ≤ 100 cells/μl were tested for serum cryptococcal antigen (sCrAg). Individuals with sCrAg titre ≥ 1:2 were treated with high-dose fluconazole. Cox proportional hazard models of Kaplan-Meier curves were used to compare survival among individuals with CD4 ≤ 100 cells/μl in the intervention and historical control groups. RESULTS: The median age was 34 years [IQR: 29,41], 54% were female, and median CD4 was 43 cells/μl [IQR: 18,71]. Follow-up time was 1224 person-years. In the intervention group, 66% (514/782) were tested for sCrAg; of whom, 11% (59/514) were sCrAg positive. Mortality was 25% (196/782) in the intervention group and 25% (191/771) in the control group. There was no significant difference between the intervention and control group in overall survival [hazard ratio (HR): 1.1 (95%CI:0.9,1.3)] or three-month survival [HR: 1.0 (95%CI:0.8,1.3)]. Within the intervention group, sCrAg-positive individuals had significantly lower survival rates than sCrAg-negative individuals [HR:1.8 (95%CI: 1.0, 3.0)]. CONCLUSIONS: A screening and treatment intervention to identify sCrAg-positive individuals and treat them with high-dose fluconazole did not significantly improve overall survival among HIV-infected individuals with CD4 counts ≤ 100 cells/μl compared to a historical control, perhaps due to intervention uptake rates or poor efficacy of high-dose oral fluconazole.
Authors: F Menichetti; M Fiorio; A Tosti; G Gatti; M Bruna Pasticci; F Miletich; M Marroni; D Bassetti; S Pauluzzi Journal: Clin Infect Dis Date: 1996-05 Impact factor: 9.079
Authors: S Tansuphasawadikul; P N Amornkul; C Tanchanpong; K Limpakarnjanarat; J Kaewkungwal; S Likanonsakul; B Eampokalap; T Naiwatanakul; D Kitayaporn; N L Young; D J Hu; T D Mastro Journal: J Acquir Immune Defic Syndr Date: 1999-08-01 Impact factor: 3.731
Authors: Neil French; Katherine Gray; Christine Watera; Jessica Nakiyingi; Eric Lugada; Michael Moore; David Lalloo; James A G Whitworth; Charles F Gilks Journal: AIDS Date: 2002-05-03 Impact factor: 4.177
Authors: Kerrigan M McCarthy; Juliette Morgan; Kathleen A Wannemuehler; Sara A Mirza; Susan M Gould; Ntombi Mhlongo; Portia Moeng; Bonnie R Maloba; Heather H Crewe-Brown; Mary E Brandt; Rana A Hajjeh Journal: AIDS Date: 2006-11-14 Impact factor: 4.177
Authors: Cheryl A Liechty; Peter Solberg; Willy Were; John Paul Ekwaru; Ray L Ransom; Paul J Weidle; Robert Downing; Alex Coutinho; Jonathan Mermin Journal: Trop Med Int Health Date: 2007-08 Impact factor: 2.622
Authors: Paula Braitstein; Martin W G Brinkhof; François Dabis; Mauro Schechter; Andrew Boulle; Paolo Miotti; Robin Wood; Christian Laurent; Eduardo Sprinz; Catherine Seyler; David R Bangsberg; Eric Balestre; Jonathan A C Sterne; Margaret May; Matthias Egger Journal: Lancet Date: 2006-03-11 Impact factor: 79.321
Authors: Rachel M Wake; Nelesh P Govender; Tanvier Omar; Carolina Nel; Ahmad Haeri Mazanderani; Aaron S Karat; Nazir A Ismail; Caroline T Tiemessen; Joseph N Jarvis; Thomas S Harrison Journal: Clin Infect Dis Date: 2020-04-10 Impact factor: 9.079
Authors: Elizabeth Nalintya; David B Meya; Sarah Lofgren; Kathy Huppler Hullsiek; David R Boulware; Radha Rajasingham Journal: J Acquir Immune Defic Syndr Date: 2018-06-01 Impact factor: 3.731
Authors: Rachel M Wake; Nazir A Ismail; Shaheed V Omar; Farzana Ismail; Caroline T Tiemessen; Thomas S Harrison; Joseph N Jarvis; Nelesh P Govender Journal: Open Forum Infect Dis Date: 2022-04-17 Impact factor: 4.423
Authors: Lincoln Pac; Mara Murray Horwitz; Anne Marion Namutebi; Brandon J Auerbach; Aggrey Semeere; Teddy Namulema; Miriam Schwarz; Robert Bbosa; Allan Muruta; David B Meya; Yukari C Manabe Journal: J Acquir Immune Defic Syndr Date: 2015-04-15 Impact factor: 3.731